Biotron Ltd (BIT) - Total Liabilities
Based on the latest financial reports, Biotron Ltd (BIT) has total liabilities worth AU$1.16 Million AUD (≈ $821.73K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Biotron Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Biotron Ltd - Total Liabilities Trend (2000–2025)
This chart illustrates how Biotron Ltd's total liabilities have evolved over time, based on quarterly financial data. See Biotron Ltd (BIT) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Biotron Ltd Competitors by Total Liabilities
The table below lists competitors of Biotron Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Red Sky Energy Ltd
AU:ROG
|
Australia | AU$1.59 Million |
|
Eugene Special Purpose Acquisitions 4 Company
KQ:321260
|
Korea | ₩4.60 Billion |
|
BlackRock Frontiers Investment Trust plc
LSE:BRFI
|
UK | GBX14.41 Million |
|
Norwest Minerals Ltd
AU:NWM
|
Australia | AU$940.49K |
|
Knosys Ltd
AU:KNO
|
Australia | AU$7.55 Million |
|
Albion Resources Ltd
AU:ALB
|
Australia | AU$100.40K |
|
Xpon Technologies Group Ltd
AU:XPN
|
Australia | AU$16.05 Million |
Liability Composition Analysis (2000–2025)
This chart breaks down Biotron Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIT company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biotron Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biotron Ltd (2000–2025)
The table below shows the annual total liabilities of Biotron Ltd from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$428.51K ≈ $303.20K |
-41.90% |
| 2024-06-30 | AU$737.51K ≈ $521.83K |
-23.38% |
| 2023-06-30 | AU$962.49K ≈ $681.03K |
+18.31% |
| 2022-06-30 | AU$813.57K ≈ $575.65K |
+75.52% |
| 2021-06-30 | AU$463.51K ≈ $327.96K |
-45.67% |
| 2020-06-30 | AU$853.19K ≈ $603.69K |
+104.11% |
| 2019-06-30 | AU$418.00K ≈ $295.76K |
+23.78% |
| 2018-06-30 | AU$337.70K ≈ $238.95K |
-45.49% |
| 2017-06-30 | AU$619.51K ≈ $438.34K |
+78.89% |
| 2016-06-30 | AU$346.32K ≈ $245.04K |
-26.81% |
| 2015-06-30 | AU$473.18K ≈ $334.80K |
-0.31% |
| 2014-06-30 | AU$474.64K ≈ $335.84K |
+21.37% |
| 2013-06-30 | AU$391.08K ≈ $276.71K |
+103.50% |
| 2012-06-30 | AU$192.18K ≈ $135.98K |
-21.34% |
| 2011-06-30 | AU$244.32K ≈ $172.87K |
+74.16% |
| 2010-06-30 | AU$140.29K ≈ $99.26K |
-36.90% |
| 2009-06-30 | AU$222.33K ≈ $157.31K |
-47.56% |
| 2008-06-30 | AU$423.94K ≈ $299.97K |
+160.05% |
| 2007-06-30 | AU$163.02K ≈ $115.35K |
-48.75% |
| 2006-06-30 | AU$318.11K ≈ $225.08K |
+112.24% |
| 2005-06-30 | AU$149.88K ≈ $106.05K |
-2.25% |
| 2004-06-30 | AU$153.33K ≈ $108.49K |
+3.55% |
| 2003-06-30 | AU$148.08K ≈ $104.77K |
+3.63% |
| 2002-06-30 | AU$142.90K ≈ $101.11K |
+28.22% |
| 2001-06-30 | AU$111.45K ≈ $78.86K |
+406.59% |
| 2000-06-30 | AU$22.00K ≈ $15.57K |
-- |
About Biotron Ltd
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.